Skip to content

Protalix BioTherapeutics, Inc.

PLX· NYSECore metricsCIK 1006281

Biological products, except diagnostic substances175 peers

Last sale
Nov 12, 2026 · -5.90%
Market cap
$248.74M
84.32M shares
Filings
974
$21.93M
Q3 2026−1.2% FY25 yoy
$3.96M
Q3 2026N/M FY25 yoy
$4.05M
Q3 2026N/M FY25 yoy
$13.44M
Q3 2026derivedN/M FY25 yoy
$0.05
Q3 2026N/M FY25 yoy
$22.04M
Q3 2026−25.7% FY25 yoy
$248.74M
12.1×
2.9×
3.1×
6.06%
—

Twelve months to Sep 30, 2026 · derived

Price

$2.95+39.15%+$0.83past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of record

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$52.74MFY 2025
$65.49M0FY 2014FY 2019FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$52,744,000reported
FY 20242024-12-31$53,399,000reported
FY 20232023-12-31$65,494,000reported
FY 20222022-12-31$47,638,000reported
FY 20212021-12-31$38,350,000reported
FY 20202020-12-31$62,898,000reported
FY 20192019-12-31$54,693,000reported
FY 20182018-12-31$34,240,000reported
FY 20172017-12-31$21,078,000 revisedreported
FY 20162016-12-31$9,199,000reported
FY 20152015-12-31$4,364,000reported
FY 20142014-12-31$3,523,000 revisedreported

Segments

Products
Revenue by Products, FY2018 to FY2025FY2018GOODS · FY2018 · $8.98MLICENSE AND R&D SERVICES · FY2018 · $25.26MFY2019GOODS · FY2019 · $15.87MLICENSE AND R&D SERVICES · FY2019 · $38.83MFY2020GOODS · FY2020 · $16.24MLICENSE AND R&D SERVICES · FY2020 · $46.66MFY2021GOODS · FY2021 · $16.75MLICENSE AND R&D SERVICES · FY2021 · $21.60MFY2022GOODS · FY2022 · $25.29MLICENSE AND R&D SERVICES · FY2022 · $22.35MFY2023GOODS · FY2023 · $40.42MLICENSE AND R&D SERVICES · FY2023 · $25.08MFY2024GOODS · FY2024 · $52.98MLICENSE AND R&D SERVICES · FY2024 · $418.00KFY2025GOODS · FY2025 · $51.80MLICENSE AND R&D SERVICES · FY2025 · $942.00K
LineFY2025ShareChange
GOODS$51.80M98%−2.2%
LICENSE AND R&D SERVICES$942.00K1.8%+125.4%
Total$52.74M

From the 10-K filed Mar 18, 2026PLX

Biological products, except diagnostic substances

Protalix BioTherapeutics, Inc. is the 42nd largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR